XSHG
600976
Market cap618mUSD
Oct 09, Last price
27.51CNY
1D
1.96%
1Q
-0.36%
Jan 2017
-13.84%
IPO
252.92%
Name
Jianmin Pharmaceutical Group Co Ltd
Chart & performance
P/E
11.73
P/S
1.26
EPS
2.35
Div yield, %
3.34%
Shrs. gr., 5y
-0.07%
Rev. gr., 5y
6.41%
Revenues
3.35b
-4.38%
Net income
360m
-0.65%
CFO
275m
+17.19%
Dividend
Apr 28, 20260.9 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jianmin Pharmaceutical Group Co.,Ltd. operates within China, focusing on the production and distribution of traditional Chinese medicines. The company's product line features pediatric pharmaceuticals, prominently sold under its Jianmin and Longmu brand names. In addition to these offerings, Jianmin provides a range of over-the-counter (OTC) drugs, various medical and health products, and consultation services. The firm's main corporate offices are located in Wuhan, China.
Key people
Jun Wang
President, Director
Zhaoyang Cheng
Chief Financial Officer · since 2019
Zhongjiang Bu
Vice President
Kai Gao
Vice President · since 2020
Zhijun Huang
Vice President · since 2019
Xuejun Pei
Vice President · since 2019
Jie Zhou
Secretary of the Board · since 2020
Qin He
Chairman of the Board
Zhenbo Hu
Director · since 2025
Rong Pei
Director · since 2011
Siyang Wang
Director · since 2011
Liang Xu
Vice Chairman of the Board · since 2024
Dean Guo
Independent Director
Shuqu Li
Independent Director
Shilin Yang
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2021‑00 | 2020‑12 | 2020‑00 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||